Gebeliğe Bağlı İntrahepatik Kolestaz: 48 Vakanın Fetal ve Maternal Sonuçlarının Değerlendirilmesi

Abstract

Amaç: Kliniğimizde takip edilen gebeliğe bağlı intrahepatik kolestaz tanılı hastaların fetal - maternal sonuçlarının değerlendirilmesi ve bu hastaların gebelik yönetiminin tartışılması. Gereç ve Yöntem: Çalışmamızda Dicle Üniversitesi Kadın Hastalıkları ve Doğum Anabilim Dalı Obstetri kliniğine Ocak 2011 -Aralık 2015 tarihleri arasında başvuran ve gebeliğe bağlı intrahepatik kolestaz (GBİHK) tanısı alan 48 hasta incelendi. Başvuru esnasındaki bilgiler hastane arşivi ve hasta dosyaları incelenerek toplandı. Bulgular: Gebeliğe bağlı intrahepatik kolestaz tanılı hastaların ortalama yaşları 27.6±6.5 idi.. Gebelerin ortalama doğum haftaları 36.1±3.1 idi. Hastaların %48’i (n=23) otuz yedinci gebelik haftasından önce doğum yaptı. 5. dk ortalama APGAR 8.19±1.73 idi. Sezaryen ile doğum oranı %56.25 (n=27) idi. Yeni doğan yoğun bakıma kabul oranı %10.6 idi. Yenidoğan bebeklerin %76.5’i (n=39) erkek %23.5 ‘i (n=12) kız idi. Perinatal mortalite oranı %3.92 idi. Maternal mortalite izlenmedi. Sonuç: Gebeliğe bağlı intrahepatik kolestaz tanısı klinik bulgu ve laboratuvar sonuçlar ile konur. Hastalığın ayırıcı tanısı dikkatli bir şekilde yapılmalı, ayırıcı tanı üzerinde dikkatle durulmalıdır. Antenatal dönemde fetal ve maternal takip dikkatli bir şekilde yapılmalı, tedavi ve doğum süreci hastaya göre planlanmalıdır. Yüksek prematüre doğum riski nedeniyle yenidoğan yoğun bakım ihtiyacı göz önünde bulundurulmalıdır.

Keywords

• Gebelik
• intrahepatik kolestaz
• yenidoğan yoğun bakım

Due to Pregnancy İntrahepatic Cholestasis: Evaluation of Fetal & Maternal Outcomes of 48 Pregnancies

Abstract

Objective: To evaluate fetal-maternal outcomes of the pregnancies complicated by intrahepatic cholestasis and to discuss the pregnancy management in our clinic. Material and methods: In this study, Dicle University Obstetrics and Gynecology, Department of Obstetrics clinic in January 2011 -December 2015 between the applicant and pregnancy induced intrahepatic cholestasis (GBİHK) were evaluated in 48 patients diagnosed. Data were collected on admission and patients by providing hospital archive files. Results: The mean age was 27.6 ± 6.5 diagnosis of intrahepatic cholestasis of pregnancy-induced patients. The average gestational age at delivery of the patients was 36.1 ± 3.1. 48% of patients (n=23) gave birth before the thirty seventh week of pregnancy. 5 min Apgar was 8:19 ± 1.73 average. Cesarean birth rate with 56.25% (n=27), respectively. Acceptance rate was 10.6% in the newborn intensive care unit. 76.5% of newborn infants (n=39) were male and 23.5% 'i (n=12) were monitored girl. Perinatal mortality rate was 3.92%. Maternal mortality was observed. Conclusion: İntrahepatic cholestasis of pregnancy depends on the diagnosis made by clinical signs and laboratory results. The differential diagnosis of the disease must be done carefully, the differential diagnosis should be considered carefully. Antenatal maternal and fetal follow-up should be done carefully, treatment and delivery process should be planned according to the patient. Due to the high risk of premature birth neonatal intensive care needs to be taken into consideration.

Keywords

• Pregnancy
• intrahepatic cholestasis
• newborn intensive care

References

1. Kawakita T, Parikh LI, Ramsey PS et al. Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol 2015;213:570 e1-8.
2. Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstetrics & Gynecology 2014;124:120-33.
3. Gabzdyl EM, Schlaeger JM. Intrahepatic cholestasis of pregnancy. J Perinat Neonatal Nurs 2015;29:41-50.
4. Than NN, Neuberger J. Liver abnormalities in pregnancy. Best Pract Res Clin Gastroenterol 2013;27:565-75.
5. Sharma N, Panda S, Singh AS. Obstetric Outcome During an Era of Active Management for Obstetrics Cholestasis. J Obstet Gynaecol India 2016;66:38-41.
6. Arthur C, Mahomed K. Intrahepatic cholestasis of pregnancy: diagnosis and management; a survey of Royal Australian and New Zealand College of Obstetrics and Gynaecology fellows. Aust N Z J Obstet Gynaecol 2014;54:263-7.
7. Bicocca MJ, Sperling JD, Chauhan SP. Intrahepatic cholestasis of pregnancy: Review of six national and regional guidelines. Eur J Obstet Gynecol Reprod Biol 2018;231:180-7.
8. Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA. Liver disease in pregnancy. Lancet 2010;375:594-605.

9. Herrera CA, Manuck TA, Stoddard GJ et al. Perinatal outcomes associated with intrahepatic cholestasis of pregnancy. J Matern Fetal Neonatal Med 2018;31:1913-20.
10. Kurt A, Ecevit A, Kısa B, İnce DA, Tarcan A, Yanık FB. İntrahepatik Kolestazlı Gebelerin Neonatal Sonuçları. Perinatoloji Dergisi 2011;19:10-4.
11. Reyes H. The spectrum of liver and gastrointestinal disease seen in cholestasis of pregnancy. Gastroenterol Clin North Am 1992;21:905-21.
12. Mei Y, Gao L, Lin Y, Luo D, Zhou X, He L. Predictors of adverse perinatal outcomes in intrahepatic cholestasis of pregnancy with dichorionic diamniotic twin pregnancies. J Matern Fetal Neonatal Med 2019;32:472-6.
13. Garcia-Flores J, Canamares M, Cruceyra M et al. Clinical value of maternal bile Acid quantification in intrahepatic cholestasis of pregnancy as an adverse perinatal outcome predictor. Gynecol Obstet Invest 2015;79:222-8.
14. Yang J, Chen C, Liu M, Zhang S. Women successfully treated for severe intrahepatic cholestasis of pregnancy do not have increased risks for adverse perinatal outcomes. Medicine (Baltimore) 2019;98:e16214.
15. Horlocker TT, Wedel DJ, Rowlingson JC et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010;35:64-101.
16. Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomäki K. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population‐based study. Hepatology 2006;43:723-8.
17. Hirvioja ML, Kivinen S. Inheritance of intrahepatic cholestasis of pregnancy in one kindred. Clinical genetics 1993;43:315-7.
18. Germain AM, Kato S, Carvajal JA, Valenzuela GJ, Valdes GL, Glasinovic JC. Bile acids increase response and expression of human myometrial oxytocin receptor. Am J Obstet Gynecol 2003;189:577-82.
19. Ovadia C, Seed PT, Sklavounos A et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet 2019;393:899-909.
20. Shemer EAW, Stephansson O, Thuresson M, Thorsell M, Ludvigsson JF, Marschall H-U. Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study. J Hepatol 2015;63:456-61.
21. Shen Y, Zhou J, Zhang S et al. Is It Necessary to Perform the Pharmacological Interventions for Intrahepatic Cholestasis of Pregnancy? A Bayesian Network Meta-Analysis. Clin Drug Investig 2019;39:15-26.
22. Gurung V, Middleton P, Milan SJ, Hague W, Thornton JG. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst Rev 2013:CD000493.
23. Chappell LC, Gurung V, Seed PT et al. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ 2012;344:e3799.
24. Saleh M, Abdo K. Consensus on the management of obstetric cholestasis: National UK survey. BJOG 2007;114:99-103.
25. Altınbaş ŞK, Karçaaltıncaba D, Kandemir Ö, Yalvaç S. İntrahepatik Gebelik Kolestazı: 33 Vakanın Maternal ve Fetal Sonuçlarının Değerlendirilmesi. Bakırköy Tıp Dergisi. 2013;9:171-5.